- Home
- UONEK vs OTLK Comparison
UONEK vs OTLK Comparison
Compare UONEK & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UONEK | OTLK |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | 1396 | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 29.2M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | UONEK | OTLK |
|---|---|---|
| Price | $5.40 | $0.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 2.8K | ★ 3.1M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.16 |
| 52 Week High | $9.38 | $3.39 |
Technical Indicators
Market Signals| Indicator | UONEK | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 27.81 |
| Support Level | $0.68 | $0.16 |
| Resistance Level | $8.95 | $0.46 |
| Average True Range (ATR) | 0.56 | 0.03 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 19.48 | 16.32 |
Price Performance
Historical ComparisonAbout UONEK Urban One Inc. Class D
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.